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Since the discovery of calcitonin (CT) reports have questioned the physiological role of human CT in
regulating calcemia. This peptide is produced out of the CT/CGRP gene splicing along with other factors
or hormones, including somatostatin by synonymously called parafollicular cells, C thyrocytes or C cells
located in the thyroid glands. The C cells have recently been proven to originate out of the ultimo-
branchial anlage of the pharyngeal endoderm instead of the neural crest cells as indicated in all text-
books. Both blood and urine CT and procalcitonin (proCT) found in human and other mammals can also
be secreted by cells located outside the thyroid glands. Taking account of dietetic calcium intake, CT
assists in the homeostasis of bone mineral mass during growth, lactation, and pregnancy, hypo- and
hyper gravity along with other paracrine thyroid secretions. Excess CT level in tissue ﬂuids, needle as-
pirations and, now proCT, can diagnose sepsis, medullary thyroid or other carcinomas; caution to be
taken with ectopic CT and gender-difference levels. Salmon CT as diurnal oral delivery seems, if proven
not toxic, best suited to continue preventing or treating several defects, especially osteoporosis,
orthopedic-related pains, perinatal or acute, fatal hypercalcemia. Contemplating old with recent physi-
ological clinical results, human longitudinal morphologic and molecular data dealing with C cells and
their paracrine interactions are few while only animal studies make us know much about CT. Human
samples out of biopsies or cadavers should be further endeavored from development to aging to fully
correlate normal with extreme or peculiar pathologies.
© 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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‘Plus est en vous’ [There is more in you]
House Van Gruuthuse, Brugge.
Like many other hormones, pathologic observations and ex-
periments that lead to the discovery of the calcitonin (CT) were
performed under pathologic rather than normal physiological
conditions out of small mammals (e.g. dogs, rats, pig, guinea pig).
Initial observations were made by removal of the thyroid and
parathyroid glands of dogs in Sanderson's laboratory [1,2]. Later,
further observations about CT involved the delivery of a very high
dose of calcium to dogs, rats and sheep that resulted in a signiﬁcant
fall in blood calcium and regulated phosphate uptake observed
after parathyroidectomy [1e15]. These data led these authors to
claim the existence of a new hormone whose crucial role is to
control the body ﬂuids' level or ‘tone’ of calcium, i.e. calcemia.
Originally, and wrongly though, this hormone has been thought to
be released by the parathyroid glands, so the large number of
publications dealing with parathyroid [e.g. Refs. [1e13]]. It was only
a year later after the original observations [3] that the same group
followed by others demonstrated that the C cells in rat and dog
thyroid glands were the true source of CT [13]. This 32-amino acid
protein hormone was isolated and puriﬁed out and proven to
originate from those C cells of the thyroid gland. Hence the name
‘thyrocalcitonin’ or ‘calcitonin’ to indicate its origin and function of
the hormone [16e20]. Both terms are accepted by theWorld Health
Organization and used in pharmaceutics.
Sources of CT have also been extracted from ultimobranchial
bodies of domestic fowl and ﬁshes and this CT have been formu-
lated to be used as medication [21e23]. Salmon CT (sCT) has been
found to be most physiologically active CT to treat hypercalcemia
[21,22] and osteoporosis [23].
This survey was initiated after previous observations describing
crinophagy in the thyroid glands in both C and T thyrocytes of
genetically obese rats [24] where one became intrigued about CT
functions since this rat strain survived with high, toxic calcemia
[22,23,25,26].
Based on earliest data, this report adds not only the newest
information about the embryological origin of the C cells with the
intent to comfort and stimulate further morphologic biomedical
studies and their interrelationships with the adjacent thyroid gland
cells and tissues to encourage further studies to clarify some
paracrine functions and pathology already known through
comparative physiology or histopathology.
Even though CT was the topic of several reviews [e.g. Ref. [27]],
especially, another more recent one [28], it was found necessary to
add this survey to encompass not only those very recent crucial
developmental ﬁndings in regards with normal development butalso to convey the difﬁculties to obtain precious old data out of
human tissues buried in archival state. Data from C cells from fetal
to aging are needed to comfort the physiologic status of C cells,
found to be interacting with the T thyrocytes because CT can
regulate calcemia and is a marker for other pathologic etiologies of
neo- or perinatal status and other diseases, including sepsis, bone
repairs, ageing, and cancers. Finally, the usage of synthetic CT (sCT)
is also evoked because this medication needed to acutely reduce a
high and toxic serum calcium level, to treat osteoporosis as well as
pain associated with bone surgeries may have a carcinogenetic
activity. However, this warning based on statistics [29] appears in
another study to suggest no such toxicity [30]. This ambiguity is
hopefully further evaluated for possible therapy against osteopo-
rosis along with toxic inﬂuence needs to be further veriﬁed to
exploit its clinical utilization.
2. The anatomical basis: terminology, discovery, new
developmental aspects
2.1. Terminology and location
The most recently published international Terminologia Histo-
logica [31] has recommendednaming the thyroid follicle's epithelial
components T thyrocytes or follicular cells. Adjacent to these follicle
cells arepale-wedged shapedcells. Inhumansamples, these cells are
few, often isolated or paired within the same epithelial lining,
named C thyrocytes, C cells or parafollicular cells. These C cells
encompass the same gland's epithelium but typically are prevented
by T thyrocytes' junctional complexes to reach the follicles' lumina
while their secretory apices discharge CT and small quantities of
other peptides such as serotonin, thyrotropin-releasing hormone
[7,8] aswell as somatostatin [32e39] associatedwith the Calcitonin-
Gene Related Peptide/Calcitonin (CGRP/CT) gene products as in the
circulatory system via fenestrated capillaries located near the basal
aspects of the thyroid follicles and with facilitated paracrine diffu-
sion or through undeﬁned, intercellular contacts as shown in ro-
dents [24,32e37,39]. In rabbit [38], like in rat [39], a unique co-
localization of CT with somatostatin or somatostatin-like peptide
was also demonstrated. In addition,more C cells are in the right lobe
than the left thyroid lobe and none in the isthmus [40].
2.2. Discovery
Hazard [41] recalled the detection of the C thyrocytes or C cells
in 1875 by E Creswell Baber [42] in dog thyroid glands and named
them ‘parenchymatous cells’. The C thyrocytes were also recog-
nized in the thyroid gland follicles by many authors [e.g. out of
[41]]: ‘parafollicular cells’ [43e45], ‘macrothyrocytes’ [46], ‘inter-
follicular cells’ [47], ‘neurohormonal cells’ [48], ‘giant-light cells’
[49], ‘argyrophil cells’ [50,51], ‘light cell’ [52] and, surprisingly,
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tology, histochemistry and ultrastructural aspects can be read along
with many publications dealing with the thyroid structure, some
are old, very interesting when accessible often with high cost [for
example, in Refs. [54e96]]. It is unfortunate that a very large
number of publications describing the microscopic anatomy of
human and animal C cells are currently considered as archives in
most large libraries and in biomedical citation sites because many
of these pioneered ultrastructural studies date from the 1960s’.
Their content is often available as titles in those sites and eventually
only available at high cost for today's investigators. The frustration
about these unreadable archives is that signiﬁcant information
become ignored by new investigators or considered ‘archaic’ even
though they could comfort other current data. Similar studies done
in the past with ultrastructure aspects must ignominiously
recommence, in animals and human samples, at cost of people's
efforts and grants of research agencies or charities.
2.3. Newly found developmental origin and histology of the C
thyrocytes
Today many textbooks still proclaim that C cells derived from
Amine Precursor Uptake and Decarboxylase (APUD) aka Diffuse
Neuroendocrine System (DNES) cells [97e101]. These cells were
thought to arise from the mesectodermal neural crest [102e104]
which then settle the T thyrocytes within the same basal lamina.
Using immunohistochemistry with molecular markers along with a
detailed morphologic thyroid development and his broad basis of
data obtained throughout his career on the thyroid tissues, Kameda
and collaborators [105e110] demonstrated in murine and other
mammals that not only C thyrocytes but also T thyrocytes and
thymus would derive from the ultimobranchial anlage, out of the
pharyngeal endoderm lineage and producing, among others,
chromogranin A, CGRP, somatostatin along with CT. These endo-
dermal precursor cells required, among others, the transcription
factors and signaling molecules Pax9, Tbx1, Ripply3, Pbx1, Mash1
(Ascl1), Hes1, Nkk2.1 (TTF-1), Pax3, Shh, FRS2a, Eya1, EphA4, Hox3
paralogs (Hoxa3, Hoxb3, Hoxd3), Pax8. Others already found that
Eya1 gene is needed to differentiate into functional C cells [111].
Without speciﬁc molecular markers C cells' origin was also evoked
by others [32,33,112e114] with the possibility evolving into
different subtypes in normal development or interactive paracrine
and endocrine inﬂuences [32,33,38,40,93,113e115] as noted in
Ref. [24]. The inﬂuence of the pituitary on C cells has already been
assumed in one old reference [116]. In addition, with somatostatin
[38,40,93] another publication indicated that sympathetic activity
can modify their activity [117].
While teaching human microscopic anatomy to students, it has
always been intriguing to note that C thyrocytes were scarce among
the thyroid follicles, contrarily to most small mammals that dis-
played many C cells taking residence within the thyroid follicles'
epithelia. In some cases, their population appears large enough to
become as replacing part of the interstitial, loose connective tissue
adjacent to the follicles. Histometry and non-equal distribution
among the twin lobes of the thyroid gland have been studied
[40,118e121]. A recent review (without text access) seems to
conﬁrm Kameda's group and others, cited above, however without
study of the migration and interactions with connective and nerve
tissues [122].
Extracted from Ref. [24] on can illustrate this large population of
C thyrocytes in Zucker rats as found in the FA/? (Fig. 1) less abun-
dant than in the fa/fa thyroid (Fig. 2 aeb) as recently studied
compared with those found in dog (Fig. 3) and in human thyroids
(Fig. 4) [123]. One can recall that fa/fa rats carry a leptin receptor
homozygous defect associated with a complexmetabolic syndromethat favors obesity caused by non-insulin dependent diabetes
mellitus and hypothyroidism in which crinophagy was discovered
in both C and T thyrocytes [24]. Furthermore, other undetermined
cell types were noted aggregated with the typical C cells in these
obese rats.
These observations can comfort much earlier data that showed a
signiﬁcant reduction of CT expression and serum release in the
obese rats [124e127]. These obese rats develop reproductive deﬁ-
ciency but can survive by some unclear homeostatic balance
bearing near toxic, high serum calcium levels [123e133] while
assuming, as reported, a typical aging bone structure [124]. In
addition, eluded in Ref. [24] as reviewed in diverse mammals,
including human, where some functional interdependence be-
tween both C and T thyrocytes are reported [32,34,35,93,134e137].
Somatostatin can similarly modulate CT as, for example, insulin-
growth factors and thyroid hormone [32,34,36e39,133]. Thus, in-
teractions between C and T thyrocytes can also be suspected with
connective tissue cells and innervation [93,138].
Incidentally, this survey on functions of CT in human was orig-
inally stimulated by this unpredicted, bizarre physiology found in
the obese rodents because if calcium receptors are found on the C
cells, these cells seem deﬁcient in the leptin mutated fa/fa rats as
noted in Ref. [24].
3. Calcitonin production
The human C thyrocytes produce the alpha-calcitonin gene that
encodes a small family of peptides that include calcitonin (CT),
katacalcin and calcitonin-gene related peptide (CGRP). Both CT and
katacalcin peptides are produced from one precursor along with
CGRP from the alternative splicing of the CGRP/CT gene located on
human chromosome 11, that brings either alpha and beta CGRP
isoforms, categorized as neuropeptides [35e37,137]. The regulation
of CT gene expression and activities has already been studied in the
peculiar obese Zucker rats [128e130]. CT half-life is quite short and
level varies with age and sex [139e143], per thyroid damage or
excision [145e148].
4. Calcitonin physiology
The following paragraphs are to note that most data about CT
seems to indicate that this hormone alone, with interrelated
ectopic one e possibly along with some of the co-secreted super-
family of CT and sex steroids with calcium-rich food intake - an-
tagonizes parathyroid hormone (PTH) activities. CT is regulating a
normal calcemia through maintenance of bone mineralization, and
preventing its depletion like in osteolysis which results in calcium
release in serum that can be balanced by capture of calcium from
nutrients as well as retrieving phosphate in vivo and in vitro.
Altogether, these activities make a valuable, signiﬁcant physiologic
role in skeletal homeostasis during the entire mammal's life cycle,
especially when dynamic bone remodeling occurs during preg-
nancy and lactation. However, due to some overall decreased ac-
tions or of their receptors and intracellular messengers, CT and
hormone co-adjuvants (superfamily, estrogens, etc) are unable to
prevent the progressive decay favoring osteoporosis or other pa-
thologies. Indeed, in normal physiology, CT stimulates the pro-
duction of calcitriol or 1, 25-dihydroxycholecalciferol (1, 25(OH)
2D) after calcidiol is transported to the proximal tubules of the
kidneys where it is hydroxylated at the 1-a position. The enzyme
25-hydroxyvitamin D3 1-alpha-hydroxylase catalyzes the conver-
sion of calcidiol into calcitriol, the active hormonally active
metabolite as vitamin D. Activation of the ligand of the vitamin
receptor enhances the level of calcium (Ca2þ) in the blood by
increasing the uptake of calcium from the gut into the blood.
Fig. 2. AeB: One-mm thick sections of obese (fa/fa) young male Zucker rat thyroid;
toluidine blue stain. Both A and B micrographs illustrate the abundance of C cells
surrounding the thyroid follicles compared with the lean thyroids. The well-contrasted
T thyrocytes (T) appear distorted by the swollen, poorly used colloid of the follicles and
by their surrounded crowds of parafollicular or C cells that show less stained. Many C
cells appear with small and blue dark variable sized granulations and organize as if cell
layers are in arcuate rows (arrows) under the stretched follicular cells also containing
accumulated dark granulations. The vascular component appears poorly represented
around these follicles when compared to those viewed lean rats. Scales equal 10 mm
[out of 24].
Fig. 3. Five mm thick parafﬁn section of a dog thyroid, stained by H&E with Saffron C
cells are indicated by arrows.
Fig. 1. One-mm thick section of lean (Fa/?) young male Zucker rat thyroid; toluidine
blue stain. A well-contrasted, simple cuboidal epithelium lines the follicles and,
amongst them, a few poorly contrasted clusters of C cells are easily recognized (ar-
rows). Note the numerous capillaries dilated but empty due to the perfusion. Scale is
10 mm.
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Through their receptors, CT main function appears to control the
inhibition of the osteoclasts' activity with the consequence of
lowering the serum calcium level [1,5,13,145e148] even though CT
half-life and signaling is somewhat short as opposed to that of PTH.5. CT and human growth and ageing
5.1. Fetal
Building a bone skeleton already suggests that during the fetal
and early postnatal periods a likely transient increased population
of C thyrocytes with abundant secretion occurs mainly until some
late adolescent age while ossiﬁcation and maturation of the bone
skeleton attained its greatest extent, then this cell populationFig. 4. Five mm thick parafﬁn section of a human thyroid, stained by H & E with
Saffron. Both 3 and 4 scales equal 10 mm and kindly obtained from an area of the digital
microscope histology set www.histology.be of the University of Namur Medical School
C cells are indicated by arrows.
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note the absence of any morphologic correlations in human lon-
gitudinal studies that ultimately would correlate with the obvious,
less invasive physiologic studies. Kameda and collaborators showed
that both C thyrocytes and T thyrocytes derived from the ultimo-
branchial pharyngeal endoderm lineage and can produce somato-
statin along with CT as well as other paracrine or co-localized
hormones. This somatostatin production appears transiently in the
murine fetus and gradually decreases with age, also in other
mammals [107e110]. However, other studies have indicated so-
matostatin production postnatally and throughout life
[32e34,37e39,134e137].
Kovacs and others [149e151] indicated that, pregnancy elevates
serum CT and fetal CT level is higher than maternal levels in utero.
They also wrote that ‘ … apart from responding appropriately to
changes in the serum calcium concentration, little evidence of an
essential role for CT in fetal mineral homeostasis can be found’.
Altogether one can suggests that the increased CT with sex steroids,
prolactin, placental lactogen and IGF-1 (as well as other unknown
factors) associate each other's activity in a sort of ballet where each
hormone/dancer accomplishes a choreographic ﬁgure that is well
deﬁned (but not known entirely) and, in the course of each
arabesque, interacts with some or all of the other hormones/com-
ponents in a performance that results in the increased absorption of
calcium by intestines, kidneys and from the skeletal system pro-
gressive bone mineralization as early as two-months in-utero. Bi-
opsies demonstrated osteoclastic activity occurring as early as 10-
week gestation while bone mass density studies did not
adequately describe this physiological axis in-utero [149e151].
However, they also indicated that acute changes in bone minerali-
zation during pregnancy do not seem to cause long-term changes in
skeletal calcium content. One would here interpret that this bone
remodeling can be viewed to accommodate dynamic developmental
changes while increasing bone mineralization occurs in the growing
skeletal tissues. As scant as the data are, only a few signiﬁcant in vitro
observations with human fetal tissues and trans iliac crest biopsies
veriﬁed that CT has anti-osteoclastic activity [152,153].
5.2. Peri- and postnatal
In several readings [149e152,154] one noted that ‘… In humans,
1, 25(OH) 2D rises to adult levels over the ﬁrst 48 h of postnatal life,
likely in response to the rise in parathyroid hormone (PTH). Serum
CT rises 2- to 10-fold over cord blood levels over the same time
interval and then gradually declines. However, ‘ … in infants that
are premature, often develop hypocalcemia along with asphyxia
and need extracorporeal oxygenation (or ECMO). These ‘premies’
can develop seizures [149e151,154,155] because the loss of
placental regulation and other defects, including maternal diabetes
and hypomagnesemia with high perinatal CT [150]. Consequently,
hypercalcitoninemia has been suggested to cause neonatal hypo-
calcemia. However, other studies indicate that the postnatal rise in
CT levels does not correlate to the fall in serum calcium [152e154].
In addition, these premature babies could eventually maintain fetal
pulmonary neuroepithelial bodies with secretions that perturb
homeostatic calcemia [156]. The same authors indicated that about
‘6-week postpartum, CT level returns to normal level’ [151,154,155].
Reports in veterinary investigations seem to comfort human data
[157,158]. In some cases, hyperparathyroidism and pseudohypo-
parathyroidism require increased calcitriol in view of absent PTH
[151,154,155]. Finally, it is noted that ‘… mice lacking CT gene lose
twice the normal amount of bone mass calcium during lactation’.
Thus, CT physiological action seems to protect against an excessive
bone mineral resorption during that life period [159e162]. It is
well-noted by the same authors [152,161e163]:’ … whether CTplays a similar role in human physiology is unknown’ but most of
these important physiologic data are unfortunately without
morphologic support in humans.
5.3. Calcitonin's effect on bone tissue is age and sex dependent
In adolescents, whether male or female, serum CT decreases
with age [139e146,164e167]. However, CT maintains a higher level
in male than females, especially during postmenopausal ages.
There is a similar difference after a hypercalcemic challenge where
the response in males is more signiﬁcant than in females
[139,142,168,169].
Through its receptors, and from a few critical data in vitro
[81,146,154], CT's main function again appears to control the inhi-
bition of the osteoclasts' activity or formation out of stem mono-
blasts in the marrow with the resulting, general effect of lowering
the serum calcium and phosphate levels [1,5,13,81,170] even
though CT half-life is somewhat short [18,145,146,159].
If most biochemical or clinical measurements are sporadically
available since long ago from aged humans, one had no opportu-
nities obtaining some published morphologic reports dealing with
normal human aging C cells [e.g. Refs. [66,67]] but only old animals.
The hypo calcemic effect of CT - along with CGRP - in mature
animals is minimal against osteopenia [169, 170] like CT null mice
[171e174]. Calcitriol or vitamin D receptors also inhibits the release
of CT as noted in cats [175], thus reducing blood calcium primarily
by inhibiting calcium release from bone [176] while the effect of CT
on renal excretion is disputed and response is age-dependent un-
less an active osteolytic bone disease is present [166e168,177].
The major effect of menopause on the skeletal bone mass is a
dominant increase in bone turnover with resorption. This may be
contributed by both the reduction of intestinal and renal absorption
of calcium, hence the body is more prone to fracture. It is more
frequent in women than men, probably caused by the decreased
anabolic actions of estrogens, thyroxin and other bone growth
factors on osteoblasts or their hormonal desensitization as osteo-
porosis sets [166,167], reviewed in Ref. [168]. In a few clinical
studies, a prolonged recovery time for CT out of induced hyper-
calcemia in longer during ageing [e.g. Ref. [169]]. Furthermore, the
mean basal CT level in women is generally lower than that of men.
The infusion of calcium or pentagastrin in women resulted in a
minimal or undetectable response in plasma CT whereas men
showed a signiﬁcantly greater increase. This relative deﬁciency in
women may likely predispose them to an increase in osteoclast
activity and bone loss, especially after menopause through low CT
in osteoporosis [166e168].
5.4. Calcitonin is not solo player but performs with others members
of the same family
The CT family members are small peptide hormones, involved in
calcium homeostasis, vertebrate osteogenesis and osteoblast
function [178]. In mammals, six CT family member peptides have
been identiﬁed, which include calcitonin gene-related peptide
alpha and beta (aCGRP and bCGRP), amylin, adrenomedullin 1
(ADM1), adrenomedullin 2 (ADM2 or intermedin) and calcitonin
receptor-stimulating peptide (CRSP) [178,179] with distinct effects
on bone cells. Calcitonin superfamily also encompasses amylin,
calcitonin gene-related peptide, and adrenomedullin [180,181].
There are 2 types of receptors for CT, one for the CT (type I) and
another for the sCT (type II). Even though type II provide a CT
preferred conformation, type I requires other activity-modifying
proteins [182e185].
Whether in conjunction with calcium and phosphate homeosta-
sis, the distribution of CT receptorse alongwith the CTectopic sites -
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throughout the body of mammals and human is vast, puzzling, and
still in need of further clariﬁcations. Morphologic investigations and
the support of newest molecular tools should further allow exciting
discoveries that can still bemade inendocrine studies. Let usmention
as examples the CT receptors detected among diverse tissues and
organs: bone marrow osteocytes [152,171,173,180,181,186e188],
lymphocytes [189], central nervous system and pituitary [190], GI
tract (especially stomach oxyntic and G cells and pathology
[191e194], kidney [177,195,196], lung [156,197,198] and heart
[199e201].
Taking a speciﬁc example in relationship with what is stated in
the former paragraph, an intramuscular CT injection interferes to
decrease gastrin production in old patients (60 and 82 years of age).
One could also question: is it only the stomach and intestinal
gastrin without the gastrin made in the central nervous system?
[see Ref. [230]]. In addition, large doses of pentagastrin or glucagon
have been shown to stimulate CT secretion but only cause a slight
increase in plasma CT in comparison to calcium infusion. However,
the relationship between gastrin and CT has yet to be identiﬁed and
but it could be ectopic in cases of peptic defects [192,194].
CT receptor diversity and its association to cancers can be of
diagnostic but also complicated by its ectopic sources [156,178].
One can think at the recent discovery about the endodermal origin
of the C cells [110]. This basic ﬁnd alone could reshufﬂe studies
about CT paracrine and endocrine interrelationships with thyroid
and other hormones.
Looking back in some comparative endocrine reports [202], one
cannot ignore some apparent contradictory function of CT on cal-
cemia homeostasis that has been published long ago: CT does not
directly alter calcium metabolism in thyroidectomized pigs [203].
In rodents, a meal results in a reduced PTH secretion due to calcium
entry via absorption in the digestive tract [204,205] or antibodies
against CT comforted those data [206]. Other observations in hy-
pocalcemia and hypothyroidism do not necessarily assist in un-
derstanding CT functions [207,208] because C cells metabolic
interactions have been reported with T thyrocytes in many mam-
mals and even human thyroid [24,32,33,108,110]. Curiously, extra-
thyroidal tissues producing CT, found long ago [109,111,112], then
detected in humans and monkeys [209e212] have not been gran-
ted more recent investigations using combined morphology and
molecular tools, including ultrastructure to further understand
these intriguing structures.
6. CT and gravity
Long duration of spaceﬂights with hypo gravity could have
deleterious osteoclastic actions [213], in part caused by atrophy or
loss of C cells during hypo gravity and, strangely, also caused by
hyper gravity [214]. In themeantime, some sort of protection seems
possible through the secretion of an inducible 18-kDa heparin-
binding cytokine, namely pleiotrophin, also a platelet-derived
growth factor [215e217]. Following the changes causing bone
demineralization, then a recovery period to reconstruct the bone
matrix lasting several weeks is needed [218].
7. CT measurement through its precursor peptide pro-
calcitonin (proCT)
In clinical laboratories, diverse methods evolved with advances
in technologies to evaluate CT plasma and urine level [219,228].
Early data displayed variability due to product degradation or
technical procedures among laboratories [177,180,219,220]. Later,
normal and cancer patients CTcan be found as monomer and dimerforms in both body ﬂuids as well as the presence of pro-calcitonin
(proCT) [185,221e224].
Incidentally, patients who underwent thyroidectomy have been
found to have detectable CT in both serum and urine. These obser-
vations suggest that human CT can be secreted by extrathyroidal
tissues [209e212,225] as it can be found in some bronchial tumors
bearing ‘carcinoid’ cells [156,197,209,210,224]. Similarly, the detec-
tion out of lung, thymus and other tissues [109,225] could explain an
alteration in the human interpretation of clinical results [210e215].
Furthermore, these ectopic CT data cannot be surprising since one
again should recall the endodermal origin of the C cells [107e110];
these should help understanding some of these results
[196,202e212,225]. High CT and receptors can be found in some
forms of inﬂammations, especially highly toxic sepsis [225e229] and
cancers, e, g. thyroid and medullary tumors [224,230,240e255],
ovary [231e235] and prostate [236,237].
Innovative tests have been devised by Trimboli and collabora-
tors in measuring the precursor of CT, pro-calcitonin (proCT),
instead of CT and to be less laborious and sensitive technique,
indicative of pathophysiologic disorders [237e239]. In all, ﬁne
needle aspiration (FNA) technique [228,238e240] is consistent
with measurements of the ﬂuidic samples for CT or, likely proCT.
Difﬁcult clinical cases can be resolved with imaging as technetium
scintigraphy, PET and other combined methodologies, preceding or
after surgical intervention [238].
8. Medullary thyroid carcinoma (MTC) and other CT defects
When high CT serum concentration is routinely measured in
patients, it is mostly caused by a medullary thyroid carcinoma
(MTC) [147,220,228e252]. This type of tumor does cause hypo-
calcaemia and some of the clinical symptoms include ﬂushing,
diarrhea, and/or weight loss.
Although serum CT concentration is being used to diagnose
MTC, it is a sensitive test but not a speciﬁc marker because other
pathologies than MTC, such as neuroendocrine tumors and
hypergastrinemia, can also result in high basal CT levels, as noted in
several previous paragraphs. For uncommon clinical cases, CT-
negative MTC, it has been recommended to perform an ultra-
sound evaluation of the cervical region and calcium stimulus with
measurements using electroluminescence immunoassay (ECLIA)
for the follow-up of such cases [228,238,252].
Deﬁciency of CT is rare and occurs after total excision of the
thyroid in some MCT, then serum CT level obviously disappears
[147,210] (if no ectopic sources) proving again that CT is essentially
produced by C cells.
Finally, in both female andmale patients, serum CTcan be found
elevated in progression along with malignant ovarian [231e235]
and prostate cancer [236,237] as a response to high calcemia.
9. Chronic kidney disease (CDK) and calcitonin
CDK is characterized by a loss of renal functions over a long period
and results in inability to excretewastes, to reabsorbminerals, and to
form calcitriol. This insufﬁciency of calcitriol, with hypocalcemia and
hyperphosphatemia, causes an increase in PTH synthesis and secre-
tion [253,254]. Renal failure can often result in local parathyroid hy-
pertrophy, cysts or benign parathyroid carcinomas. Thus, in patients
with CKD, this secondary hyperparathyroidismwith high serum PTH
level causes an imbalance in thehomeostaticmechanismscontrolling
bone minerals eventually leading to renal osteodystrophy [255]. CT
does not seem to play a protective role in these patients and stay at
normal serum level despite the high levels PTH. Hence, does CT
protect the body from excessive PTH activity or would this alteration
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10.1. Calcemia
There is little doubt that CT can balance calcemia through in-
ternal secretions especially in regards of acute or malignant hy-
percalcemia [148,256,257] but does not appear to act while
osteopetrosis is developed [258].10.2. Osteoporosis
Out of the original discovery, natural sources have been
searched for it to be applied therapeutically against osteoporosis
[259e262]. Testing slaughtered fowl and out of ﬁsheries, salmon,
extracted salmon CT (sCT) was found to be best source and more
active [1,14,20e23] to help maintain bony skeleton while osteo-
porosis develops [263e272]. The ﬁsh sCT either oral or spray seems
adequate clinically for managing acute hypercalcemia in patients
but its effect lasts only for a week, longer than human CT for its
favorable pharmaceutical properties [263e273]. A series of ongoing
studies started in 2008 showed sCT taken orally by day seems
favorable against osteoporosis or osteoarthritis defects [262e271].
However, new data are developed while this survey is written and
submitted to this journal.10.3. Orthopedic or bone-related defects
Other osteopathic defects have been experimented with sCT to
treat vertebral fractures [274,275], pertrochanteric or other bone
fractures [276,277]. In addition to the management of lumbar spi-
nal stenosis (LSS) [278,279]. Insofar multiple studies have shown
that sCT reduces pain caused by osteoporotic vertebral compression
fractures, bone metastases, Paget's disease of bone [256] and
adolescent idiopathic scoliosis [280].
Several researchers evaluated the effect of salmon CT using the
visual analogue scale (VAS) in patients who suffer from lumbar
spinal stenosis (LSS). One of the studies concluded that intramus-
cular injection of low dose CT on patients with LSS does improve
bone pain in patients suffering from severe low back pain but has
no effect onwalking distance [279]. Another group investigated the
effect of sCT as a therapeutic agent to alleviate anastrozole-induced
bone pain in patients who suffer breast cancer e they found CT can
act as an analgesic and effective to reduce bone pain; they also
reported it had no effect on bone loss during cancer treatment
[281] or bone pain associated with diabetes [282].10.4. Low calcemia and ECMO
In case of hypocalcemia the adjustments made in critical illness
calls for intravenous calcium [283e285], no mention is made about
CT level [284] contrarily with premature infants
[149e151,154,155,286,287] when high CT occurs perinatally.11. Toxic effects of sCT?
CT is most widely used parenterally, however oral and nasal
formulations are also available [21e23,262,263]. An isolated study
reported an association between sCT use and cancer [29]. However,
another recent study claims no carcinogenetic association [30]. This
point of contention or ambiguous data should also be reviewed
soon considering the ongoing sCT clinical trials [272].12. Conclusion
The function of CT in humans is to be associated or to control the
dynamics of bone growth and its homeostasis during fetal, youth,
adulthood and decreased in ageing. It seems to prevail during the
periods of high calcium demands dealing with bone remodeling,
especially after fractures and the physiologic calcemia needed
during lactation. In these instances, some animal studies suggest CT
acts on the kidneys to favor an increased production of the active
form of vitamin D to help meet the high body calcium demands
along with some of the PTH activities by intervening in colonic
reabsorption of calcium from the diet instead of using bone min-
erals as a mineral source. Other inﬂuences of paracrine hormones
or signaling factors can interact with the C cells where most syn-
thesis and release of CT occurs, including of some ectopic sites,
likely lungs and thymus.
Even though a plethora of studies have been made on the hu-
man thyroid in basic and clinical investigations and some aspects of
C cells and CT physiology remain a puzzle [27,28] The newly
discovered common endodermal origin from the ultimobranchial
body of the C and T thyrocytes (and other associated cells that
probably disappear in fetus or soon after birth in human) may
induce some studies. Especially new C cells' developmental and
longitudinal human research studies to be done, ﬁrst noninvasive,
such as ﬂuid measurements. In addition, morphology and molec-
ular techniques added to ethical cadaveric studies would improve
the understanding of ageing aspects about those C cells regarding
the thyroid gland and the etiology of rare pathologies to foreseen
new therapeutic strategies.Acknowledgements
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